Unknown

Dataset Information

A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.


ABSTRACT:

Background

Recurrent/metastatic adenoid cystic carcinoma (ACC) is an incurable disease with no standard treatments. The majority of ACCs express the oncogenic transcription factor MYB (also c-myb), often in the context of a MYB gene rearrangement. This phase II trial of the tyrosine kinase inhibitor (TKI) axitinib (Pfizer) tested the hypothesis that targeting pathways activated by MYB can be therapeutically effective for ACC.

Patients and methods

This is a minimax two-stage, phase II trial that enrolled patients with incurable ACC of any primary site. Progressive or symptomatic disease was required. Patients were treated with axitinib 5 mg oral twice daily; dose escalation was allowed. The primary end point was best overall response (BOR). An exploratory analysis correlating

SUBMITTER: Ho AL 

PROVIDER: S-EPMC5035791 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature